CRISPR Therapeutics AG has announced updates on its clinical development programs across multiple therapeutic areas. The company has advanced CTX310, an in vivo gene editing therapy targeting ANGPTL3, into Phase 1b clinical trials for severe hypertriglyceridemia and refractory hypercholesterolemia, following positive Phase 1 results that demonstrated significant and durable reductions in triglycerides and low-density lipoprotein with a favorable safety profile. Additionally, CTX320, targeting LPA, showed reductions of up to 73% in the dose escalation phase, and a next-generation LPA program, CTX321, is in IND/CTA-enabling studies. In the autoimmune and oncology space, zugocabtagene geleucel (zugo-cel; formerly CTX112) is undergoing Phase 1 clinical trials in several autoimmune indications and a Phase 1/2 trial in B-cell malignancies. Early clinical data in systemic lupus erythematosus patients have been reported, showing sustained drug-free clinical remission and B cell depletion. The company's regenerative medicine portfolio also includes CTX211, which has demonstrated detectable C-peptide levels 12 months after implantation in clinical studies, supporting the transition to next-generation candidate CTX213, currently progressing towards clinical development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CRISPR Therapeutics AG published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-009880), on January 12, 2026, and is solely responsible for the information contained therein.